FIGURE 7.
Effects of SERMs and their combinations with DBT on ALP activity and ERE luciferase activity of MG-63 cells. Human osteosarcoma MG-63 cells treated with DBT at 1.0 mg/ml were co-treated with different concentration (10-12–10-6 M) of tamoxifen and raloxifene in PRF DMEM containing 5% cs-FBS for 48 h. (A) Dose-dependent effects of tamoxifen alone and in combination with DBT on ALP activity; (B) dose-dependent effects of raloxifene alone and in combination with DBT on ALP activity; (C) dose-dependent effects of tamoxifen alone and in combination with DBT on ERE luciferase activity; (D) dose-dependent effects of raloxifene alone and in combination with DBT on ERE luciferase activity. Data are expressed as mean ± SEM. Results were from two independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. control; ∧p < 0.05, ∧∧p < 0.01, ∧∧∧p < 0.001 vs. tamoxifen or raloxifene alone. n = 3. Interactions between SERMs and DBT were analyzed by two-factor ANOVA.